Editing Clinical Trials (section)

=== Nivolumab Plus Ipilimumab — CheckMate 743 Long-term Data ===

CheckMate 743 remains the only Phase 3 trial demonstrating survival improvement sustained over 3 years with first-line immunotherapy in unresectable malignant pleural mesothelioma.<ref>[https://mesothelioma.net/treatment-for-mesothelioma/ Mesothelioma Treatment Options], Mesothelioma.net</ref>

'''Three-Year Follow-up Results:'''
* '''Three-year overall survival:''' 23.2% versus 15.4% with chemotherapy
* '''Sustained benefit:''' Observed regardless of histology
* '''Duration of response:''' Longer with dual immunotherapy at 3 years
* '''Safety:''' Consistent profile with no new signals at long-term follow-up

{| style="width:90%; margin:1.5em auto; background:#f8f9fa; border-left:4px solid #1a5276; border-radius:0 4px 4px 0;"
|-
| style="padding:20px 25px 15px; font-style:italic; font-size:1.05em; line-height:1.6;" | "Clinical trials represent the cutting edge of mesothelioma treatment. We encourage every patient to explore trial options because tomorrow's standard treatments are available today through these programs. The survival improvements we're seeing with newer therapies are remarkable."
|-
| style="padding:5px 25px 20px; text-align:right;" | '''— Paul Danziger,''' Founding Partner, Danziger & De Llano
|}